3 results on '"Baldi, Giacomo Giulio"'
Search Results
2. Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes
- Author
-
Nora Drove, Giuseppe Badalamenti, Angelo Paolo Dei Tos, Emanuela Palmerini, Morena Caira, Andrea Marrari, Annalisa Trama, Giacomo Giulio Baldi, Bruno Vincenzi, Giovanni Grignani, Antonella Brunello, Trama, Annalisa, Badalamenti, Giuseppe, Baldi, Giacomo Giulio, Brunello, Antonella, Caira, Morena, Drove, Nora, Marrari, Andrea, Palmerini, Emanuela, Vincenzi, Bruno, Dei Tos, Angelo Paolo, Grignani, Giovanni, Trama A., Badalamenti G., Baldi G.G., Brunello A., Caira M., Drove N., Marrari A., Palmerini E., Vincenzi B., Dei Tos A.P., and Grignani G.
- Subjects
Registrie ,medicine.medical_specialty ,Cancer Research ,Histology ,Epidemiology ,Cancer registrie ,Soft Tissue Neoplasms ,Disease ,European reference network ,Patient care ,Clinical expertise ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Prevalence ,Humans ,Cancer registries ,Registries ,030212 general & internal medicine ,Stage (cooking) ,Intensive care medicine ,Soft tissue sarcoma ,Reference centres ,business.industry ,Incidence ,Italian rare cancer network ,Regional variability ,Oncology ,Reference centre ,Cancer ,Sarcoma ,medicine.disease ,Italy ,030220 oncology & carcinogenesis ,Patient Care ,business ,Large group ,Human - Abstract
Sarcomas are rare malignant neoplasms that develop from mesenchymal cells and include a heterogeneous and large group of histological subtypes that may occur at any anatomical site. Soft tissue sarcomas (STS), the focus of this review, account for ≈70‒80% of sarcomas and represent
- Published
- 2019
3. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial
- Author
-
Paolo G. Casali, Robert J. Grimer, P. D. Sander Dijkstra, Hans Gelderblom, Emanuela Palmerini, Andrzej Pieńkowski, Michal Wagrodzki, Domenico Andrea Campanacci, Stefano Ferrari, Louie Gaston, Piotr Rutkowski, Michael Parry, Alessandro Gronchi, Giacomo Giulio Baldi, Guido Scoccianti, Aneta Borkowska, Silvia Stacchiotti, Rutkowski, Piotr, Gaston, Louie, Borkowska, Aneta, Stacchiotti, Silvia, Gelderblom, Han, Baldi, Giacomo Giulio, Palmerini, Emanuela, Casali, Paolo, Gronchi, Alessandro, Parry, Michael, Campanacci, Domenico Andrea, Scoccianti, Guido, Wagrodzki, Michal, Ferrari, Stefano, Dijkstra, Sander, Pieńkowski, Andrzej, and Grimer, Robert
- Subjects
0301 basic medicine ,Male ,medicine.medical_treatment ,0302 clinical medicine ,Retrospective Studie ,Femur ,Neoadjuvant therapy ,Aged, 80 and over ,Bone Density Conservation Agents ,RANKL ,General Medicine ,Middle Aged ,Primary tumor ,Curettage ,Giant cell tumor of bone ,Europe ,Survival Rate ,Denosumab ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Female ,Giant-cell tumor of bone ,medicine.drug ,Human ,Adult ,medicine.medical_specialty ,Bone Density Conservation Agent ,Adolescent ,Bone Neoplasms ,Bone Neoplasm ,Disease-Free Survival ,03 medical and health sciences ,Young Adult ,medicine ,Humans ,Survival rate ,Retrospective Studies ,Aged ,Neoplasm Staging ,Dose-Response Relationship, Drug ,Tibia ,business.industry ,medicine.disease ,Surgery ,Radiation therapy ,Radiography ,030104 developmental biology ,Osteonecrosis of the jaw ,business - Abstract
Background Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely metastazing bone tumor. This is a retrospective study evaluating a large series of GCTB patients treated with denosumab in routine practice in 6 European reference centers. Methods Patients with locally advanced, unresectable or metastatic GCTB, treated with denosumab outside clinical trials were eligible. Primary end-point was progression-free survival (PFS) for all patients; secondary end-points were: type of surgery, relapse rate and event-free survival for patients after preoperative denosumab + surgery. Results We identified 138 patients treated in the period 2011–2016. In 40/43 cases the diagnosis was confirmed by H3F3A gene mutation. Median follow-up time was 23 months (range 6–48). Primary tumor was located in lower limb (38%) - mostly in femur and tibia, in upper limb (34%), and in pelvis/axial skeleton/ribs (28%). 110 (80%) patients had primary tumors, 28 (22%) recurrent tumors after previous surgical procedures (+/− radiotherapy). 89/138 patients had locally advanced GCTB and underwent neoadjuvant denosumab. The median denosumab treatment duration was 8 months (median number of cycles 11), 98% had clinical benefit from therapy. 39 (44%) had wide en-bloc resection - WE (+implantation of the prosthesis in 17 cases), the other 50 (56%) cases had intralesional curettage - C. Progression after surgical treatment was observed in 19 patients, 16 of them after C (32%); 13 patients underwent denosumab re-challenge, and all responded. Two-year progression-free survival (PFS; from denosumab start) rate was 81%; 2-year EventFS (from surgery) was significantly better in WE group (93%) vs 55% in C group (p = 0.006). Treatment was well tolerated with only 2 cases of grade 3 toxicity and one osteonecrosis of the jaw. Conclusion Our retrospective study confirms that denosumab is extremely efficient in unresectable/metastatic disease as well as in a neoadjuvant setting. Our data confirm excellent efficacy and short-term tolerability of this drug. Our data suggest that neoadjuvant therapy with denosumab is the option for treatment of initially locally advanced tumors to facilitate complete surgical resection or avoid mutilating surgery. The risk of recurrences after curettage of GCTB following denosumab raises questions about the optimal management of such cases.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.